TOP - May 2021 Vol 14, No 3

Momelotinib, a selective and orally bioavailable inhibitor of Janus kinase (JAK) 1, JAK2, and ACVR1, improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis, according to updated findings from the phase 3 SIMPLIFY-1 and SIMPLIFY-2 clinical trials presented at ASH 2020.

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 13, 2021, and April 23, 2021.